Trials / Terminated
TerminatedNCT01263366
Exploratory Study of Norepinephrine to Prevent Radiodermatitis in Breast Cancer Patients
Exploratory Study of Topical Norepinephrine in Post-Surgical Breast Cancer Patients Receiving Radiotherapy
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- ProCertus BioPharm, Inc · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study, a nonrandomized open-label Phase I safety and exploratory study, will evaluate the safety of topical norepinephrine in post-surgical breast cancer patients who are undergoing radiation therapy. The study will also provide information about whether topical norepinephrine can prevent or decrease the severity of the radiation dermatitis experienced by these patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Norepinephrine | Approximately 1.6 or 4.6 mL of a 400 mM norepinephrine solution will be applied topically to a portion of the radiation treatment field prior to each radiation treatment (20-33 treatments) |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2013-04-01
- Completion
- 2013-04-01
- First posted
- 2010-12-20
- Last updated
- 2013-04-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01263366. Inclusion in this directory is not an endorsement.